Clinical Trials Logo

Plaque-type Psoriasis clinical trials

View clinical trials related to Plaque-type Psoriasis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT02660580 Completed - Psoriasis Clinical Trials

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

AURIEL-PsO
Start date: February 16, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.

NCT ID: NCT02016105 Completed - Clinical trials for Plaque Type Psoriasis

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

ADACCESS
Start date: December 2013
Phase: Phase 3
Study type: Interventional

The aim of the study is to demonstrate equivalent efficacy and similarity in the safety profile of GP2017 and Humira® in patients with moderate to severe chronic plaque-type psoriasis.

NCT ID: NCT01876875 Completed - Clinical trials for Plaque-type Psoriasis

n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis

PSO
Start date: April 2007
Phase: Phase 4
Study type: Interventional

Low-grade systemic inflammation associated with obesity may worsen the clinical course of psoriasis. Both a low-calorie diet and nutritional supplementation have been shown to have an impact on the clinical course of psoriasis, including an anti-inflammatory effect of n-3 polyunsaturated fatty acids (PUFAs). This study aimed to assess the effectiveness of an energy-restricted diet, enriched in n-3 PUFAs and poor in n-6 PUFAs, on metabolic markers and clinical outcome of obese patients with psoriasis. Methods: Forty-four obese patients with mild-to-severe plaque-type psoriasis treated with immuno-suppressive drugs were randomized to assume either their usual diet or an energy-restricted diet (20 kcal/kg/ideal body weight/day) enriched of n-3 PUFAs (average 2.6 g/d). All patients continued their immuno-modulating therapy throughout the study. End-point measures included anthropometric, biochemical and clinical parameters at baseline, 3 and 6 months.

NCT ID: NCT01646567 Completed - Clinical trials for Plaque Type Psoriasis

SHP-141C in Plaque Type Psoriasis

Start date: September 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and clinical activity of the SHP-141C topical cream formulations in patients with plaque type psoriasis.

NCT ID: NCT01636687 Completed - Clinical trials for Plaque-type Psoriasis

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

JUNCTURE
Start date: October 17, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.

NCT ID: NCT01412944 Completed - Clinical trials for Plaque-type Psoriasis

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

STATURE
Start date: December 2011
Phase: Phase 3
Study type: Interventional

The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.

NCT ID: NCT01258088 Completed - Clinical trials for Plaque-type Psoriasis

Safety Study of Ointment for the Treatment of Plaque-type Psoriasis

AN2728-PSR-104
Start date: November 30, 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine how much drug is absorbed throughout the body after being applied to the skin.

NCT ID: NCT01132612 Completed - Clinical trials for Plaque-type Psoriasis

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

Start date: May 11, 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.

NCT ID: NCT00852761 Completed - Clinical trials for Plaque-Type Psoriasis

A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis

Start date: March 2009
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.

NCT ID: NCT00773734 Completed - Psoriasis Clinical Trials

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

Start date: September 1, 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.